Additionally, FGF-21 has been proposed as a non-invasive biomarker for distinguishing MASLD from healthy controls, with levels correlating with liver stiffness.16 These findings underscore FGF-21’s potential as a valuable marker for assessing disease severity, particularly in obesity-driven MASLD. The gene discussed is FGF21; the disease is obesity disorder.